← Back to Search

Cancer Vaccine

Cancer Vaccine for Melanoma

Phase 3

Waitlist Available

Research Sponsored by CancerVax Corporation

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Must have had all clinically-detectable disease surgically removed

Must have Stage IV melanoma

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing a cancer vaccine to see if it can prevent the return of melanoma.

Who is the study for?

This trial is for patients with Stage IV melanoma who have had all visible cancer removed surgically. Participants must not be on immune-compromising medications, including some steroids and radiation therapies, and must not have HIV or Hepatitis A, B, or C.Check my eligibility

What is being tested?

The study is testing the effectiveness of CancerVax™ vaccine in preventing or delaying the return of melanoma after surgical removal of tumors in a Phase III clinical setting.See study design

What are the potential side effects?

While specific side effects are not listed here, vaccines like CancerVax™ could potentially cause reactions at the injection site, flu-like symptoms, allergic responses, and may affect the immune system.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

All visible signs of my disease were removed with surgery.

Select...

My melanoma is at stage IV.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

CancerVax CorporationLead Sponsor

2 Previous Clinical Trials

1,118 Total Patients Enrolled

2 Trials studying Melanoma

1,118 Patients Enrolled for Melanoma

Media Library

CancerVax™ Vaccine (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT00052156 — Phase 3

CancerVax™ Vaccine (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00052156 — Phase 3

Melanoma Clinical Trial 2023: CancerVax™ Vaccine Highlights & Side Effects. Trial Name: NCT00052156 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How do I sign up for this opportunity to help with this research?

"This melanoma study has the capacity to enroll 670 individuals that are 18-80 years old. To be eligible, potential participants cannot be taking any medication or engaging in any therapies which could weaken their immune system. Additionally, all surgery related to the cancer must be completed before beginning this trial."

Answered by AI

Would elderly patients be suitable for this kind of treatment?

"This particular clinical trial is only open to adults aged 18-80. Out of the 821 total trials, 53 are for patients under 18 years old and 768 are for seniors over the age of 65."

Answered by AI

Can this medication be legally prescribed in the United States?

"This medical intervention has been determined to be safe, as it is a Phase 3 trial. This means that there is efficacy data as well as multiple rounds of safety data supporting this claim."

Answered by AI

Are several research centers conducting this clinical trial in Canada?

"There are 52 enrolment sites for this trial, but the primary locations are Hoag Memorial Hospital Presbyterian in Newport Beach, California; University of Arkansas for Medical Sciences in Little Rock, Arkansas; and Kaiser Permanente Medical Group in Anaheim, New jersey."

Answered by AI

Recent research and studies

Annals of SurgeryJournal

Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma

Hoshimoto, Sojun, Mark B. Faries, Donald L. Morton, Tatsushi Shingai, Christine Kuo, He-jing Wang, Robert Elashoff, et al.. 2012. “Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma”. Annals of Surgery. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/sla.0b013e3182380f56.

Annals of Surgical OncologyJournal

Long-term Survival After Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases

Faries, Mark B., MMAIT-IV Clinical Trial Group, Nicola Mozzillo, Mohammed Kashani-Sabet, John F. Thompson, Mark C. Kelley, Ronald C. DeConti, et al.. 2017. “Long-term Survival After Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases”. Annals of Surgical Oncology. Springer Science and Business Media LLC. doi:10.1245/s10434-017-6072-3.

clinicaltrials.govStudy

Vaccine Therapy for Patients With Stage IV Melanoma

2024. "Vaccine Therapy for Patients With Stage IV Melanoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00052156.

All > Stage Iv Melanoma